Trastuzumab-Associated Osteoporosis Risk
Trastuzumab (Herceptin) is not a recognized major cause of cancer-treatment–induced bone loss in breast cancer compared with estrogen-depleting endocrine therapies such as aromatase inhibitors and ovarian suppression. [1]
Cancer-related osteoporosis risk in breast cancer survivorship is primarily linked to estrogen deprivation from aromatase inhibitors (and ovarian suppression) and to glucocorticoid exposure rather than to trastuzumab. [1]
Bone Loss Agents With Established Associations
Major therapies associated with increased fracture risk in hormone receptor–positive breast cancer include:
- Aromatase inhibitors (bone loss and fracture risk increase compared with tamoxifen). [2]
- Ovarian suppression therapies (estrogen deprivation contributing to secondary osteoporosis). [1]
- Chronic glucocorticoids (secondary osteoporosis risk). [1]
Evidence Base for Trastuzumab
Clinical bone-health guidance for cancer treatment–induced bone loss centers on aromatase inhibitors/ovarian suppression and glucocorticoids as the key driver therapies for fracture risk assessment and prevention strategies. [1]
In this guidance framework, trastuzumab is not identified as a primary osteoporosis or fracture risk factor requiring the same baseline and ongoing bone-specific monitoring strategy as aromatase inhibitors/ovarian suppression. [1]
Practical Clinical Implications
Bone risk assessment and preventive measures are recommended for breast cancer patients receiving aromatase inhibitors or ovarian suppression based on fracture risk tools and bone mineral density testing strategies described in survivorship and cancer–bone health guidance. [1]
Osteoporosis prevention planning should therefore focus on endocrine therapy–related risk factors and glucocorticoid exposure rather than on trastuzumab as the causal driver. [1]